[Report] Oncology Apoptopic Drugs Market Research, Trends, Analysis TOC

1. Executive Summary
2. About Cancer Highlights
3. Methodologies
4. Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5. Introduction
6. Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets
7. The Cancer Genome Project and Apoptopic Drug Targets
- 7.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
8. Protein Expression Profiles of Apoptopic Drug Targets in Human
- 8.1 Expression in Normal Tissues and Cancer Tissues
- 8.2 Expression in Human Cancer Cell Lines and Primary Cells
9. Pathway Analysis of Drug Targets of Apoptopic Drugs
10. Protein-Protein Interactions Between Identified Apoptopic Drug Targets
11. Available Biological Structure Data on Apoptopic Drug Targets
12. Drug Target Profiles of Apoptopic Drug Targets in Oncology
- 12.1.1 Auxiliary transport protein activity
- 12.1.2 Carboxy-lyase activity
- 12.1.3 Catalytic activity
- 12.1.4 Cell adhesion molecule activity
- 12.1.5 Chaperone activity
- 12.1.6 Complement activity
- 12.1.7 Cysteine-type peptidase activity
- 12.1.8 Cytokine activity
- 12.1.9 DNA topoisomerase activity
- 12.1.10 Glutathione transferase activity
- 12.1.11 Hormone activity
- 12.1.12 Hydrolase activity
- 12.1.13 Intracellular ligand-gated ion channel activity
- 12.1.14 Kinase activity
- 12.1.15 Kinase regulator activity
- 12.1.16 Ligase activity
- 12.1.17 Lipid kinase activity
- 12.1.18 Metallopeptidase activity
- 12.1.19 Molecular function unknown
- 12.1.20 Motor activity
- 12.1.21 Oxidoreductase activity
- 12.1.22 Peptide hormone
- 12.1.23 Peroxidase activity
- 12.1.24 Protein binding
- 12.1.25 Protein serine/threonine kinase activity
- 12.1.26 Protein threonine/tyrosine kinase activity
- 12.1.27 Protein-tyrosine kinase activity
- 12.1.28 Receptor activity
- 12.1.29 Receptor binding
- 12.1.30 Receptor signaling complex scaffold activity
- 12.1.31 Receptor signaling protein serine/threonine kinase activity
- 12.1.32 RNA binding
- 12.1.33 Structural constituent of cytoskeleton
- 12.1.34 Superoxide dismutase activity
- 12.1.35 T cell receptor activity
- 12.1.36 Transcription factor activity
- 12.1.37 Transcription regulator activity
- 12.1.38 Transferase activity
- 12.1.39 Translation regulator activity
- 12.1.40 Transmembrane receptor activity
- 12.1.41 Transmembrane receptor protein tyrosine kinase activity
- 12.1.42 Transporter activity
13. Apoptopic Drug Target Mix by Development Stage
14. Apoptopic Drug Target Mix by Cancer Indication
- 14.1 Basal Cell Cancer
- 14.2 Biliary Cancer
- 14.3 Bladder Cancer
- 14.4 Bone Cancer
- 14.5 Brain Cancer
- 14.6 Breast Cancer
- 14.7 Carcinoid Tumor
- 14.8 Cervical Cancer
- 14.9 Chemotherapy-induced Neutropenia
- 14.10 Colorectal Cancer
- 14.11 Endometrial Cancer
- 14.12 Fallopian Tube Cancer
- 14.13 Gastrointestinal Cancer
  - 14.13.1 Gastrointestinal Stomach Cancer
  - 14.13.2 Gastrointestinal Stromal Cancer
- 14.14 Head and Neck Cancer
- 14.15 Leukemia
  - 14.15.1 Acute Lymphocytic Leukemia
  - 14.15.2 Acute Myelogenous Leukemia
  - 14.15.3 Chronic Lymphocytic Leukemia
  - 14.15.4 Chronic Myelogenous Leukemia
- 14.16 Liver Cancer
- 14.17 Lung Cancer
  - 14.17.1 Non-Small Cell Lung Cancer
  - 14.17.2 Small Cell Lung Cancer
- 14.18 Lymphoma
  - 14.18.1 B-cell Lymphoma
  - 14.18.2 Hodgkin' s Lymphoma
  - 14.18.3 non-Hodgkin' s Lymphoma
  - 14.18.4 T-cell Lymphoma
- 14.19 Melanoma
- 14.20 Mesothelioma
- 14.21 Myelodysplastic Syndrome
- 14.22 Myeloma
- 14.23 Nasopharyngeal Cancer
- 14.24 Oesophageal Cancer
- 14.25 Oral Cancer
- 14.26 Ovarian Cancer
- 14.27 Pancreatic Cancer
- 14.28 Peritoneal Cancer
- 14.29 Prostate Cancer
- 14.30 Renal Cancer
- 14.31 Sarcoma
  - 14.31.1 Leiomyo Sarcoma
- 14.32 Squamous Cell Cancer
- 14.33 Testicular Cancer
- 14.34 Thymoma Cancer
- 14.35 Thyroid Cancer
15. Apoptopic Drugs and their Targets by Companies
- 15.1 Australia
- 15.2 Canada
- 15.3 China
- 15.4 Denmark
- 15.5 Germany
- 15.6 Israel
- 15.7 Japan
- 15.8 South Korea
- 15.9 Spain
- 15.10 Switzerland
- 15.11 Taiwan
- 15.12 United Kingdom
- 15.13 USA
16. Disclaimer
17. Drug Index
18. Company Index

4.1 List of Figures

Figure 1: Distribution of Compound Types Among Apoptopic Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets

4.2 List of Tables

Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs
Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs
Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets
Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets
Table 13: Number of Available Biological Structures on Apoptopic Drug Targets
Table 14: Overview of Drug Target Profile Themes
Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage
Table 16: Apoptopic Drug Target Mixes by Development
Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication
Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug
Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type Developmental Stage of Drug
Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to Compound Type and Developmental Stage of Drug
Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug
Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug
Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug
Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug
Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug
Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug
Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug
Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug
Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia
Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada
Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China
Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark
Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany
Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel
Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan
Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea
Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain
Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland
Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan
Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom
Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA

The Drug Target Atlas of Apoptopic Drugs in Oncology

Table of Contents

4.1 List of Figures

4.2 List of Tables